oncologie; cancer du sein; traitement systémique; médecine personnalisée; traitement ciblé; chimiothérapie; hormonothérapie; oncology; breast cancer; systemic therapy; precision medicine; targeted therapy; chemotherapy; endocrine therapy
Résumé :
[fr] Dans cet article, les auteurs passent en revue les grands principes de prise en charge du traitement systémique du cancer du sein et posent la question suivante : jusqu'où réellement aujourd'hui ce traitement est-il individualisé ? Les nouvelles technologies permettent une analyse détaillée des anomalies génomiques au niveau des cellules cancéreuses. Malheureusement, nous n'avons pas encore compris comment utiliser au mieux ces données au bénéfice du patient. La majorité des modifications du génome sont des évènements relativement rares compliquant le développement de nouveaux médicaments dans le cadre d'une médecine de précision. De plus, les tumeurs présentent une grande hétérogénéité temporelle et spatiale dont il faudra tenir compte lors de ce développement. Une collaboration internationale intensive est en cours pour tenter de confirmer que la médecine de précision permet d'optimiser les résultats du traitement systémique dans le cancer du sein.
Disciplines :
Oncologie
Auteur, co-auteur :
JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
COLLIGNON, Joëlle ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Josse, Claire ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine
SCHROEDER, Hélène ; Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie
RORIVE, Andrée ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
FRERES, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
LAMBERT, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Ferlay J, Parkin DM, Steliarova-Foucher E., Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 2010, 46, 765-81.
http://www.kankerregister.org/media/docs/SKRstats/2012/2012-F-BEL-Abs.pdf, consulté le 28/4/2015.
De Angelis R, Sant M, Coleman MP, et al., Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5 -A population-based study. Lancet Oncol, 2014, 15, 23-34.
Goldhirsch A, Winer EP, Coates AS et al., Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 2013, 24, 2206-23.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Comparisons between different polychemotherapy regimens for early breast cancer: Meta-Analyses of long-Term outcome among 100,000 women in 123 randomised trials. Lancet, 2012, 379, 432-44.
Coudert B, Asselain B, Campone M, et al., Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: The 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist, 2012, 17, 900-9.
Petrelli F, Borgonovo K, Cabiddu M, et al., Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: A meta-Analysis. Breast Cancer Res Treat, 2012, 135, 335-46.
Carlson RW, Hudis CA, Pritchard KI: Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: Evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw, 2006, 4, 971-9.
Francis PA, Regan MM, Fleming GF, et al., Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med, 2015, 372, 436-46.
Davies C, Pan H, Godwin J, Gray R, et al., Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 2013, 381, 805-16.
Gray RG, Rea D, Handley K, et al., aTTom: Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol, 2013, 31 suppl, abstr 5.
Goss PE, Ingle JN, Martino S, et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med, 2003, 349, 1793-802.
Perez EA, Romond EH, Suman VJ, et al., Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol, 2014, 32, 3744-52.
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al., 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet, 2013, 382, 1021-8.
Piccart-Gebhart MJ, Holmes AP, Baselga J, et al., First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol, 2014, 32 suppl, abstr LBA4.
Finn RS, Crown JP, Lang I, et al., The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol, 2015, 16, 25-35.
Yardley DA, Noguchi S, Pritchard KI, et al., Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther, 2013, 30, 870-84.
Swain SM, Baselga J, Kim SB, et al., Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med, 2015, 372, 724-34.
Verma S, Miles D, Gianni L,et al., Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med, 2012, 367, 1783-91.
Gyrffy B, Hatzis C, Sanft T, et al., Multigene prognostic tests in breast cancer: Past, present, future. Breast Cancer Research, 2015, 17, 11.
Buyse M1, Loi S, van't Veer L, et al., Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. J Natl Cancer Inst, 2006, 98, 1183-1192.
Sun Z, Prat A, Cheang MC, et al., Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes,waiting for TAILORx and RxPONDER. Ann Oncol, 2015, 26, 70-4.
Cardoso F, Piccart-Gebhart M, Van't Veer L, et al., The MINDACT trial: The first prospective clinical validation of a genomic tool. Mol Oncol, 2007, 1, 246-51.
Andre F, Mardis E, Salm M, et al., Prioritizing targets for precision cancer medicine. Ann Oncol, 2014, 25, 2295-303.
Stover DG, Wagle N., Precision medicine in breast cancer: Genes, genomes, and the future of genomically driven treatments. Curr Oncol Rep, 2015, 17, 15.
https://clinicaltrials.gov/ct2/show/NCT02102165?term=aurora+breast&rank=1, consulté le 16/5/2015
André F, Bachelot T, Commo F et al., Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol, 2014 Mar, 15, 267-74.
Guttery DS, Page K, Hills A et al., Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem, 2015. Epub ahead of print.
Rothé F, Laes JF, Lambrechts D, et al., Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol, 2014, 25, 1959-65.
Turner N, Pestrin M, Galardi F, et al., Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel). 2014, 6, 684-707.
